Role for 5‑day, once-daily extended-release clarithromycin in acute bacterial exacerbation of chronic bronchitis

References

• Adkison JD, Konzem SL. Management of acute exacerbations of chronic obstructive pulmonary disease. Pharmacotherapy 2001;21:929–9
   PubMed Web of Science ®Google Scholar
• Blanchard AR. Treatment of COPD exacerbations. Pharmacologic options and modification of risk factors. Postgrad Med 2002;111:65–8, 71–2, 75
   Google Scholar
• Chodosh S. Bronchitis and asthma. In: Gorbach SL, Bartlett JL, and Blacklow NR, editors. Infectious Diseases. Philadelphia: W.B. Saunders Co., 1992. pp.476–85
   Google Scholar
• Niederman MS. Antibiotic therapy of exacerbations of chronic bronchitis. Semin Resp Infect 2000;15:59–70
   PubMedGoogle Scholar
• Sethi S. Infectious exacerbations of chronic bronchitis: diagnosis and management. J Antimicrob Chemother 1999;43(Suppl A):97–105
   Google Scholar
• Aubier M, Aldons PM, Leak A, et al. Telithromycin is as effective as amoxicillin/clavulanate in acute exacerbations of chronic bronchitis. Respir Med 2002;96:862–71
   PubMed Web of Science ®Google Scholar
• Chodosh S, DeAbate CA, Haverstock D, et al. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. Respir Med 2000;94:18–27
   PubMed Web of Science ®Google Scholar
• DeAbate CA, Bettis R, Munk ZM, et al. Effectiveness of short- course therapy (5 days) with grepafloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis. Clin Ther 1999;21:172–88
   PubMed Web of Science ®Google Scholar
• File T, Schlemmer B, Garau J, et al. Gemifloxacin versus amoxicillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis. The 070 Clinical Study group. J Chemother 2002;12:314–25
   Google Scholar
• Fogarty CM, Bettis RB, Griffin TJ, et al. Comparison of a 5 day regimen of cefdinir with a 10 day regimen of cefprozil for treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 2000;45:851–8
   PubMed Web of Science ®Google Scholar
• Gotfried MH, DeAbate CA, Fogarty C, et al. Comparison of 5-day, short-course gatifloxacin therapy with 7-day gatifloxacin therapy and 10-day clarithromycin therapy for acute exacerbation of chronic bronchitis. Clin Ther 2001;23:97–107
   PubMed Web of Science ®Google Scholar
• Gotfried M, Notario G, Spiller J, et al. Comparative efficacy of once daily, 5-day short-course therapy with clarithromycin extended-release versus twice daily, 7-day therapy with clarithromycin immediate-release in acute bacterial exacerbation of chronic bronchitis. Curr Med Res Opin 2005;21:245–54
   PubMed Web of Science ®Google Scholar
• Grassi C, Casali L, Curti E, et al. Efficacy and safety of short course (5-day) moxifloxacin vs 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis (AECB). J Chemother 2002;14:597–608
   PubMed Web of Science ®Google Scholar
• Guest N, Langan CE. Comparison of the efficacy and safety of a short course of ceftibuten with that of amoxycillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis. Int J Antimicrob Agents 1998;10:49–54
   PubMed Web of Science ®Google Scholar
• Hoepelman IM, Mollers MJ, van Schie MH, et al. A short (3-day) course of azithromycin tablets versus a 10-day course of amoxycillin-clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long-term outcome. Int J Antimicrob Agents 1997;9:141–6
   PubMed Web of Science ®Google Scholar
• Langan C, Clecner B, Cazzola CM, et al. Short-course cefuroxime axetil therapy in the treatment of acute exacerbations of chronic bronchitis. Int J Clin Prac 1998;52:289–97
   PubMed Web of Science ®Google Scholar
• Langan CE, Zuck P, Vogel F, et al. Randomized, double-blind study of short-course (5 day) grepafloxacin versus 10 day clarithromycin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother 1999;44:515–23
   PubMed Web of Science ®Google Scholar
• Lorenz J. Comparison of 5-day and 10-day cefixime in the treatment of acute exacerbation of chronic bronchitis. Chemotherapy 1998;44(Suppl 1):15–8
   PubMed Web of Science ®Google Scholar
• Masterton RG, Burley CJ. Randomized, double-blind study comparing 5- and 7-day regimens of oral levofloxacin in patients with acute exacerbation of chronic bronchitis. Int J Antimicrob Agents 2001;18:503–12
   PubMed Web of Science ®Google Scholar
• McCarty JM, Pierce PF. Five days of cefprozil versus 10 days of clarithromycin in the treatment of an acute exacerbation of chronic bronchitis. Ann Allergy Asthma Immunol 2001;87:327–34
   PubMed Web of Science ®Google Scholar
• O’Doherty B, Daniel R. Treatment of acute exacerbations of chronic bronchitis: comparison of trovafloxacin and amoxicillin in a multicentre, double-blind, double-dummy study. Trovafloxacin Bronchitis Study Group. Eur J Clin Microbiol Infect Dis 1998;17:441–6
   Google Scholar
• Paster RZ, McAdoo MA, Keyserling CH, et al. A comparison of a five-day regimen of cefdinir with a seven-day regimen of loracarbef for the treatment of acute exacerbations of chronic bronchitis. Int J Clin Prac 2000;54:293–9
   PubMed Web of Science ®Google Scholar
• Schaberg T, Ballin I, Huchon G, et al. A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbation of chronic bronchitis. J Intern Med Res 2001;29:314–28
   PubMed Web of Science ®Google Scholar
• Sethi S, Breton J, Wynne B. Efficacy and safety of pharmaco- kinetically enhanced amoxicillin-clavulanate at 2000/125 milli- grams twice daily for 5 days versus amoxicillin-clavulanate at 875/125 milligrams twice daily for 7 days in the treatment of acute exacerbations of chronic bronchitis. Antimicrob Agents Chemother 2005;49: 153–60
   Google Scholar
• Wilson R, Kubin R, Ballin I, et al. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1999;44:501–13
   PubMed Web of Science ®Google Scholar
• Wilson R, Schentag JJ, Ball P, et al. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin Ther 2002;24:639–52
   PubMed Web of Science ®Google Scholar
• Guay DRP. Short-course antimicrobial therapy of respiratory tract infections. Drugs 2003;63:2169–84
   PubMed Web of Science ®Google Scholar
• Anzueto A, Norris S. Clarithromycin in 2003: sustained efficacy and safety in an era of rising antibiotic resistance. Int J Antimicrob Agents 2004;24:1–17
   PubMed Web of Science ®Google Scholar
• Guay DRP, Gustavson LE, Devcich KJ, et al. Pharmacokinetics and tolerability of extended-release clarithromycin. Clin Ther 2001;23:566–77
   PubMed Web of Science ®Google Scholar
• Adler JL, Jannetti W, Schneider D, et al. Phase III, randomized, double-blind study of clarithromycin extended-release and immediate-release formulations in the treatment of patients with acute exacerbation of chronic bronchitis. Clin Ther 2000;22:1410–20
   PubMed Web of Science ®Google Scholar
• Weiss K, Vanjaka A, Canadian Study Group on Bronchitis. An open-label, randomized, multicenter, comparative study of the efficacy and safety of 7 days of treatment with clarithromycin extended-release tablets versus clarithromycin immediate- release tablets for the treatment of patients with acute bacterial exacerbation of chronic bronchitis. Clin Ther 2002;24: 2105–22
   Google Scholar
• Adam D, Glaser-Caldow E, Wachter J, et al. Comparative efficacy of clarithromycin modified-release and clarithromycin immediate-release formulations in the treatment of lower respiratory tract infections. Clin Ther 2001;23:585–95
   PubMed Web of Science ®Google Scholar
• Nalepa P, Dobryniewska M, Busman T, et al. Short-course therapy of acute exacerbation of chronic bronchitis: A double- blind, randomized, multicenter comparison of extended-release versus immediate-release clarithromycin. Curr Med Res Opin 2003;19:411–20
   PubMed Web of Science ®Google Scholar
• Celli BR, MacNee W; TS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932–46
   Google Scholar
• O’Donnell DE, Aaron S, Bourbeau J, et al. State of the art compendium: Canadian Thoracic Society recommendations for the management of chronic obstructive pulmonary disease. Can Respir J 2004;11(Suppl B):7B–43
   Google Scholar
• Perronne C, Filipecki J, Drugeon H, et al. Efficacy and safety of clarithromycin extended-release, 5-day short-course therapy, in acute bacterial exacerbation of chronic bronchitis, comparatively to telithromycin. Med Mal Infect 2005;35:507–15
   PubMed Web of Science ®Google Scholar
• Anthonisen NR, Manfreda J, Warren CPW, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196–204
   PubMed Web of Science ®Google Scholar
• National Committee for Clinical Laboratory Standards (2000). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 5th ed. Approved Standard NCCLS Document M7-A5 and 10th Informational Supplement: M100-S10 (M7)
   Google Scholar
• National Committee for Clinical Laboratory Standards (2000). Performance standards for antimicrobial disk susceptibility tests. 7th ed. Approved Standard NCCLS Document M2-A7 and 10th Informational Supplement: M100-S10 (M2)
   Google Scholar
• Brunton S, Carmichael BP, Colgan R, et al. Acute exacerbation of chronic bronchitis: a primary care consensus guideline. Am J Manag Care 2004;10:689–96
   PubMed Web of Science ®Google Scholar
• Farrell DJ, File TM, Jenkins SG. Prevalence and antibacterial susceptibility of mef(A)-positive macrolide-resistant Streptococcus pneumoniae over 4 years of the PROTEKT US Study (2000–2004). J Clin Microbiol 2006 Nov 8; [Epub ahead of print]
   Google Scholar
• Bishai WR. Macrolide immunomodulatory effects and symptom resolution in acute exacerbation of chronic bronchitis and acute maxillary sinusitis: a focus on clarithromycin. Expert Rev Anti Infect Ther 2006;4:405–16
   PubMedGoogle Scholar
• Gotfried MH. Macrolides for the treatment of chronic sinusitis, asthma, and COPD. Chest 2004;125(Suppl):52S–60
   Google Scholar
• Clay KD, Hanson JS, Pope SD, et al. Brief communication: severe hepatotoxicity of telithromycin: three cases reports and review of the literature. Ann Intern Med 2006;144:415–20
   PubMed Web of Science ®Google Scholar